Literature DB >> 19414745

Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia.

Hong Zheng1, Catherine Matte-Martone, Dhanpat Jain, Jennifer McNiff, Warren D Shlomchik.   

Abstract

In allogeneic hemopoietic stem cell transplantation, mature donor alphabeta T cells in the allograft promote T cell reconstitution in the recipient and mediate the graft-vs-leukemia (GVL) effect. Unfortunately, donor T cells can attack nonmalignant host tissues and cause graft-vs-host disease (GVHD). It has previously been shown that effector memory T cells not primed to alloantigen do not cause GVHD yet transfer functional T cell memory and mediate GVL. Recently, central memory T cells (T(CM)) have also been reported to not cause GVHD. In contrast, in this study, we demonstrate that purified CD8(+) T(CM) not specifically primed to alloantigens mediate GVHD in the MHC-mismatched C57BL/6 (B6)-->BALB/c and the MHC-matched, multiple minor histocompatibility Ag-mismatched C3H.SW-->B6 strain pairings. CD8(+) T(CM) and naive T cells (T(N)) caused similar histological disease in liver, skin, and bowel. B6 CD8(+) T(CM) and T(N) similarly expanded in BALB/c recipients, and the majority of their progeny produced IFN-gamma upon restimulation. However, in both models, CD8(+) T(CM) induced milder clinical GVHD than did CD8(+) T(N). Nonetheless, CD8(+) T(CM) and T(N) were similarly potent mediators of GVL against a mouse model of chronic-phase chronic myelogenous leukemia. Thus, in contrast to what was previously thought, CD8(+) T(CM) are capable of inducing GVHD and are substantially different from T(EM) but only subtly so from T(N).

Entities:  

Mesh:

Year:  2009        PMID: 19414745     DOI: 10.4049/jimmunol.0802212

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease.

Authors:  Hiroki Tsukamoto; Petya Chernogorova; Korcan Ayata; Ulrike V Gerlach; Ankur Rughani; Jerry W Ritchey; Jayanthi Ganesan; Marie Follo; Robert Zeiser; Linda F Thompson; Marco Idzko
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

2.  Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.

Authors:  Yi Zhang; Ashley R Sandy; Jina Wang; Vedran Radojcic; Gloria T Shan; Ivy T Tran; Ann Friedman; Koji Kato; Shan He; Shuaiying Cui; Elizabeth Hexner; Dale M Frank; Stephen G Emerson; Warren S Pear; Ivan Maillard
Journal:  Blood       Date:  2010-09-24       Impact factor: 22.113

3.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors:  Jillian Rosenberg; Jun Huang
Journal:  Curr Opin Chem Eng       Date:  2017-12-14       Impact factor: 5.163

4.  MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.

Authors:  Takero Shindo; Tae Kon Kim; Cara L Benjamin; Eric D Wieder; Robert B Levy; Krishna V Komanduri
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

5.  Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.

Authors:  Brandon M Triplett; Brad Muller; Guolian Kang; Ying Li; Shane J Cross; Joseph Moen; Lea Cunningham; William Janssen; Ewelina Mamcarz; David R Shook; Ashok Srinivasan; John Choi; Randall T Hayden; Wing Leung
Journal:  Transpl Infect Dis       Date:  2018-01-16       Impact factor: 2.228

Review 6.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

Review 7.  Understanding memory CD8+ T cells.

Authors:  Tasleem Samji; Kamal M Khanna
Journal:  Immunol Lett       Date:  2017-03-06       Impact factor: 3.685

Review 8.  Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies.

Authors:  Ravi M Shah
Journal:  Bone Marrow Transplant       Date:  2021-03-05       Impact factor: 5.483

Review 9.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.